Male reproductive system neoplasm

Researchers are testing a vaccine called BNT113 in people whose cancers are driven by HPV16, a common virus linked to head and neck, cervical, and anogenital tumors. The trial enrolls two groups: one with head and neck cancer that has been treated and shows no signs of disease, a…

Researchers are testing a treatment called TOOKAD Soluble vascular targeted photodynamic therapy in men with localized intermediate-risk prostate cancer. The approach uses a drug activated by light to destroy cancer tissue in the prostate. The trial follows 50 men for up to 60 mo…

This phase 1 trial is testing an experimental therapeutic cancer vaccine called AST-021p in people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if the vaccine is safe and can trigger an immune response against the cancer. Participan…

This study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.

Researchers are running a Phase I trial of HG146, an experimental oral drug, in adults with advanced solid tumors or lymphoma that have worsened despite standard treatments. The study first tests HG146 alone to find a safe dose, then tests it combined with a PD-(L)1 antibody, a t…

This study tested whether taking the drug abiraterone on an on-and-off schedule could help it work longer for men with advanced prostate cancer that no longer responds to hormone therapy. Nineteen men whose cancer had already responded to standard daily abiraterone were enrolled.…

This study looked at whether a special care plan led by a geriatrician and a nurse could improve survival and quality of life for older adults (70+) with advanced cancer. 792 patients with breast, colorectal, lung, prostate, bladder, ovarian cancer, or lymphoma took part. The app…

This phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…

This early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a chemotherapy) is safe and tolerable for people with advanced solid tumors that no longer respond to standard treatments. The study included 47 adults and children aged 12 and older. Researchers aimed…

This study tests whether adding the immunotherapy drug nivolumab (Opdivo) to standard radiation and hormone therapy is safe and effective for men with a very aggressive form of prostate cancer (Gleason grade group 5). About 44 men will receive the drug combination. The goal is to…

This study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer worsening in men with metastatic hormone-sensitive prostate cancer. About 223 men will receive darolutamide plus ADT, and their results will be compared to men from an earlier study wh…

This study tested a radioactive drug called 177Lu-PSMA-617 in 62 Chinese men with advanced prostate cancer that had spread and stopped responding to hormone therapy and chemotherapy. The drug targets a protein on cancer cells and delivers radiation directly to them. Researchers m…

This study tests a radioactive drug called 177Lu-PSMA-617 in men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. The trial aims to find the safest effective dose and see if it can lo…

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…

Researchers are testing whether giving radiation therapy before sipuleucel-T, a personalized immunotherapy vaccine, works better than the vaccine alone in men with hormone-resistant prostate cancer that has spread. The trial enrolls about 51 participants and randomly assigns them…

This early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…

This phase 1 trial is testing whether a diet that severely limits arginine—an amino acid some tumors depend on—is safe and might help control solid tumors. About 25 adults with solid tumors will follow a specially designed low-arginine liquid diet for two 3-week cycles while cont…

This trial tests whether a steam-based treatment called Rezūm can work as well as standard surgery (TURP) for men with an enlarged prostate who need a catheter to urinate. Men aged 50 to 80 with this condition will be randomly assigned to receive either Rezūm or TURP. The main go…

This early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…

This Phase 3 trial tests an oral drug called QLG1080 in men with hormone-sensitive advanced prostate cancer. The goal is to see if the drug can safely lower testosterone to castration levels, which helps slow cancer growth. Participants must be eligible for endocrine therapy and …

This study looks at whether eating a high-fiber diet (over 21 grams per day) can change gut bacteria and improve the immune system's ability to fight solid tumors like colorectal cancer. About 25 adults with solid tumors will follow this diet to see if it is safe and helps with t…

This study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. The trial enrolled 186 Chinese men and was stopped early …

This trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…

This trial compares two types of radiation therapy for prostate cancer: proton therapy and standard photon therapy. The main question is whether proton therapy reduces moderate to severe urinary or intestinal side effects. Researchers will also track quality of life, cancer recur…

This phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…

This phase 1 trial tests an experimental drug called MRG003 in people with advanced solid tumors, including colorectal cancer, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma. The study aims to find a safe dose and to see whether the drug can shrink tumors. Pa…

This early-phase trial tested a shorter course of radiation for men whose prostate cancer came back after their prostate was removed. Instead of the usual 6-7 weeks of daily radiation, researchers gave higher doses over just 2-4 weeks, focusing the strongest radiation on the tumo…

This early-phase study tests an experimental drug called MK-6837, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug sh…

This phase 2 trial is testing a combination of two hormone-based drugs—darolutamide and high-dose testosterone—in 51 men with metastatic castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy. The approach, called extreme bipolar androgen…

This early-phase trial tested a combination of two drugs, vandetanib and everolimus, in 151 people with advanced or metastatic cancer that had stopped responding to standard treatments. The goal was to find the safest dose and see if the combination could slow or stop cancer grow…

This trial is testing whether a new form of chemotherapy called PLX038 can be safely combined with the PARP inhibitor rucaparib to shrink tumors in people with small cell lung cancer, small cell cancer outside the lungs, or other solid tumors. The study has two parts: first, find…

This trial is testing whether a new way of giving collagenase injections can help men with Peyronie's disease who have not improved with standard treatment. Peyronie's disease causes a curved, painful erection due to scar tissue. The study will compare men who receive up to 8 inj…

This study compared two ways of taking prostate tissue samples: the standard transrectal method (through the rectum) and a newer transperineal method (through the skin between the scrotum and anus). Over 1,000 men participated to see if the transperineal approach causes fewer inf…

This study tests a new long-acting injection called Debio 4228 for men with advanced prostate cancer. The goal is to lower testosterone levels to control the cancer. About 55 men will receive different doses to find the best one. This is not a cure, but a way to manage the diseas…

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This trial asks men with advanced prostate cancer which of two oral medications they prefer: the experimental drug ODM-201 or the approved drug enzalutamide. Both work by blocking male hormones that fuel cancer growth. Participants will take each drug for a period and then answer…

This trial tests whether using 3D on-board imaging before each radiation session improves accuracy and outcomes for men with prostate cancer compared to standard imaging. The study tracks disease-free survival, side effects, and costs over 2 to 5 years. It aims to find the best i…

This phase 3 trial is testing an investigational drug called DKF-MA102 (leuprorelin acetate) in men with advanced prostate cancer. The goal is to see if two injections, given 12 weeks apart, can safely lower testosterone levels to a target range, which may help control the cancer…

This trial tests whether a dye called indocyanine green, viewed with near-infrared imaging, can help surgeons spot pelvic lymph nodes during robot-assisted prostate removal in men with stage II prostate cancer. The dye is injected into the prostate, and the imaging system is used…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This early-stage trial is testing an investigational therapy called OH2, a modified herpes simplex virus designed to infect and destroy cancer cells while also stimulating the immune system. The study will evaluate OH2 alone or in combination with the immunotherapy drug pembroliz…

This early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…

This early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…

This early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…

This trial tests whether injecting platelet-rich plasma (PRP) — a concentrate made from a person's own blood — into the penile plaque can reduce curvature and ease symptoms in men with Peyronie's disease. Half the participants receive PRP injections and half receive a placebo (sa…

This phase 1 trial is testing an experimental drug called STP707 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see whether the drug can slow or shrink tumors. Participants receive STP707 b…

This study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …

This trial tests whether a personalized ventilation strategy, guided by electrical impedance tomography (EIT), can reduce lung complications in men undergoing robot-assisted prostate removal. During this surgery, the abdomen is inflated with gas and the patient is tilted head-dow…

This completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…

This study monitors the safety and effectiveness of the drug olaparib (Lynparza) in people with ovarian, breast, prostate, or pancreatic cancer who are prescribed it as part of routine care in South Korea. Researchers will track side effects and how long the cancer stays under co…

This early-phase trial is testing an experimental drug called SM3321 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose. Participants receive SM3321 as a we…

This phase 2 trial is testing whether surgery and radiation can help men whose prostate cancer has come back and spread to a few spots in the body. About 20 participants will receive either surgery to remove the spread tumors or targeted radiation, or both. The main goal is to se…

This early-stage trial tests an experimental drug called JS015 in people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. Up to 12 participants will recei…

This trial evaluates the Bitrack robotic system, designed to assist surgeons during laparoscopic kidney removal (partial or total) and prostate removal. The study includes 15 adults scheduled for these surgeries. The goal is to check if the robot works safely and effectively, as …

This early-stage trial tests an experimental drug called SHR-7367 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 22 participants will …

This early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of t…

This study follows nearly 1,000 prostate cancer patients taking ORGOVYX (relugolix) to see how the drug works in everyday medical practice. Researchers will track side effects, quality of life, and disease progression. The goal is to understand the drug's real-world safety and ef…

This study tested whether adding the drug niraparib to standard radiation and hormone therapy can help prevent high-risk prostate cancer from coming back. Niraparib blocks a protein that cancer cells use to repair their DNA, which may kill them. The trial enrolled 22 men with agg…

This early-phase study tests an experimental drug called ANV600, given alone or with the immunotherapy Keytruda, in 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. Beca…

This study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot…

This clinical trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard hormone therapy enzalutamide (Xtandi) helps men with a type of advanced prostate cancer called metastatic castration-resistant prostate cancer (mCRPC). The study includes men …

This early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…

This phase 2 trial tests an experimental drug called LDP, an anti-PD-L1 monoclonal antibody that helps the immune system attack cancer cells. It enrolls adults with muscle-invasive bladder cancer, non-clear cell kidney cancer, or advanced penile cancer. Participants receive LDP i…

This study tests whether combining the immunotherapy drug ipilimumab with the hormone therapy degarelix, given before and after prostate removal surgery, can control advanced prostate cancer. It includes two groups: men with newly diagnosed cancer that has spread to a few other s…

This early-stage trial is testing a combination of two lab-made antibodies in people with advanced solid tumors that have not responded to standard treatments. One antibody (LDP) aims to reactivate the immune system against cancer, while the other (CDP1) blocks a growth signal on…

This trial compares two types of hormone injections given before prostate brachytherapy (internal radiation) for early-stage prostate cancer. One injection lasts one month, the other three months, and both are used to lower testosterone to make radiation more effective. The study…

This study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…

This study tests a type of radiation called high-dose brachytherapy for men with prostate cancer that hasn't spread. Doctors place tiny radioactive sources directly into the prostate to deliver a strong dose to the tumor while sparing nearby healthy tissue. The goal is to control…

This early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…

This trial compares three modern radiotherapy techniques—helical tomotherapy and two types of dynamic arc therapy (RapidArc and VMAT)—for treating prostate, cervical, and anal canal cancers that require pelvic lymph node irradiation. The goal is to determine which method is most …

This study tests a combination of three chemotherapy drugs—gemcitabine, oxaliplatin, and paclitaxel—in people with advanced testicular cancer that has not responded to standard cisplatin-based treatment or has returned after treatment. The goal is to see if this drug combination …

This early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This study tests two drugs, saruparib and darolutamide, given alone or together before prostate removal surgery in men with newly diagnosed prostate cancer. The goal is to see how these drugs affect cancer cells and check for side effects. About 120 men with localized, higher-ris…

This study tests whether adding darolutamide to standard hormone therapy (ADT) helps Chinese men with a high-risk form of prostate cancer that has not spread but is no longer responding to hormone therapy alone. Darolutamide blocks the effects of male hormones on cancer cells, po…

This study tests a combination of three immunotherapy drugs—PDS0101, M7824, and NHS-IL12—in people with advanced HPV-related cancers such as cervical, anal, and throat cancers. The goal is to see if the mix can shrink tumors or stop them from growing. Participants receive the dru…

This small, completed Phase 1 study tested a single injection of a radioactive drug called Lutetium-177 BQ7876 in 7 men with prostate cancer. The main goals were to see how the drug spreads in the body, how much radiation reaches tumors, and whether it is safe. Because it is very…

This early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…

This phase 3 trial tested whether adding bevacizumab (Avastin) to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced urinary tract cancer live longer. 506 patients with cancer that had spread or could not be removed by surgery took part. The study compar…

This phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…

This phase 2 trial tested phenelzine sulfate (Nardil), an antidepressant, in 26 men with prostate cancer that returned after initial treatment but hadn't spread. The goal was to see if the drug could lower PSA levels, a marker of cancer activity. Researchers measured how many pat…

This study tested the safety and effectiveness of enzalutamide (Xtandi) in 52 Indian men with metastatic castration-resistant prostate cancer that had worsened after chemotherapy. Participants took enzalutamide daily while continuing hormone therapy. The main goal was to see how …

This Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…

This study tested whether giving a higher dose of radiation specifically to the visible tumor inside the prostate could improve cancer control in men with localized prostate cancer. Eighty-five men either received a standard radiation plan with an extra boost to the tumor or a co…

This study tested a new type of PET/MRI scan that uses a special tracer to find small spots of prostate cancer that standard scans miss. Men with a rising PSA after prostate surgery and radiation received targeted radiation to those spots. The goal was to see if this approach can…

This study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…

This early-stage study tests two oral drugs (darolutamide and abemaciclib) plus standard hormone therapy in men with high-risk prostate cancer that has spread or may come back. The first part finds the safest dose; the second checks if the combination can shrink or eliminate tumo…

This pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …

This completed Phase 3 study compared the risk of major heart problems between two hormone therapies—relugolix (a pill) and leuprolide (an injection)—in 387 men with prostate cancer. The trial was stopped early by the sponsor, but enrolled patients could continue treatment for up…

This phase 2 trial tested the chemotherapy drug carboplatin in 16 men with metastatic castration-resistant prostate cancer that has specific gene changes in the homologous recombination pathway. The goal was to see if carboplatin could shrink tumors or lower PSA levels. The study…

This study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This study tested a drug called ARN-509 in 127 men with advanced prostate cancer that had stopped responding to standard hormone therapy. The goal was to find a safe dose and see if the drug could lower PSA levels, a marker of cancer activity. The drug works by blocking male horm…

This study tested a device called NanoKnife to treat prostate cancer in 121 men with intermediate-risk disease. The goal was to safely destroy cancer tissue while avoiding major side effects. Researchers checked if the treated area was cancer-free after 12 months and tracked any …

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This phase II trial tested a combination of three drugs—carboplatin, cabazitaxel, and abiraterone—in 61 men with high-volume metastatic prostate cancer that still responds to hormone therapy. The goal was to see how many men had no cancer growth after one year. The study also tra…

This early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…

This study followed 354 men with low- to intermediate-risk prostate cancer who chose to freeze only the cancerous half of their prostate (hemi-gland cryoablation). Researchers tracked how well the treatment controlled the cancer and how it affected urinary function and quality of…

This study tested a new X-ray monitoring technique (KIM) during prostate cancer radiation therapy. The goal was to see if it helps doctors aim more precisely at the tumor while reducing harm to healthy tissue. 49 men with low- or intermediate-risk prostate cancer took part. The a…

This phase I trial tested a new type of radiation therapy for low- and intermediate-risk prostate cancer that delivers a higher dose each day, completing treatment in just 5 sessions over 2 weeks instead of the usual 45-48. The study enrolled 120 participants to check the safety …

This study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…

This trial tested whether a precise type of radiation called SBRT could slow the growth of metastatic prostate cancer in men whose disease was starting to worsen despite hormone therapy. 86 men with one or two growing tumors received SBRT while continuing their current hormone dr…

This study tested whether a combination of two chemotherapy drugs, gemcitabine and cisplatin, can shrink tumors in people with advanced or metastatic penile cancer. Fifty adults with inoperable or spreading disease took part. The main goal was to see how many patients responded t…

This study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…

This early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …

This early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…

This study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or pre-cancerous blood conditions (MGUS or low-risk smoldering multiple myeloma). The goal was to see if the supplement could lower canc…

This study tested a new way to give radiation therapy for prostate cancer. It used very precise, high-dose radiation over just five days. The goal was to control the cancer while reducing side effects on the bladder and bowel. 444 men with localized prostate cancer took part, and…

This early-stage trial tested the safety and best dose of adding niclosamide (a drug used for tapeworm infections) to standard hormone therapy (enzalutamide) in 6 men with advanced prostate cancer that no longer responds to hormone treatment. The goal was to see if the combinatio…

This pilot study tested a new, shorter radiation schedule (ultra-hypofractionation) in 13 men with early-stage prostate cancer. The goal was to see if this approach causes fewer urinary side effects while still controlling the cancer. Participants had low- to intermediate-risk pr…

This Phase 2 trial tested an immunotherapy drug called vudalimab, either by itself or combined with standard chemotherapy or targeted therapy, in 72 men with metastatic castration-resistant prostate cancer that had worsened after prior treatments. The main goal was to check safet…

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

This study tested a device that uses water vapor (steam) to destroy cancerous tissue in the prostate. 32 men with prostate cancer received the treatment just before their scheduled prostate removal surgery. Researchers checked how well the steam destroyed the targeted tissue and …

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…

This early-stage study tested a new drug, ARV-110, combined with the standard treatment abiraterone in 45 men with metastatic prostate cancer whose PSA levels were rising despite abiraterone alone. The main goals were to check safety and find the best dose. The study is complete,…

This study tested whether adding a prostate cancer vaccine (PROSTVAC) and chemotherapy (docetaxel) to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. 74 men with metastatic castration-sensitive prostate cancer took part. …

This large Phase 3 trial tested whether adding the immunotherapy pembrolizumab (Keytruda) to standard hormone therapy (enzalutamide plus ADT) could improve outcomes for men with metastatic hormone-sensitive prostate cancer. Over 1,200 participants were enrolled. The study was unb…

This early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…

This early study tested a new laser treatment for prostate cancer that can be done in a doctor's office. Ten men with early-stage prostate cancer received focal laser ablation guided by MRI and ultrasound images. The main goal was to see if the procedure is safe and feasible, not…

This study tested whether adding apalutamide to standard hormone therapy after prostate removal surgery can keep prostate cancer from coming back in high-risk patients. 108 men who had surgery for non-spread prostate cancer took the drug combo for up to 2 years. Researchers check…

This study tested a single, high-dose radiation treatment for men with low-risk or low intermediate-risk prostate cancer. The goal was to see how well the body tolerates this one-time treatment by tracking side effects in the bladder and digestive system within the first 6 months…

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…

This phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…

This early-phase trial tested a combination of four drugs—apalutamide, abiraterone, docetaxel, and prednisone—in 16 men with metastatic castrate-resistant prostate cancer, a form of the disease that no longer responds to standard hormone therapy. The main goal was to find a safe …

This early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…

This phase 2 trial tested a high-dose chemotherapy regimen called TICE in 101 patients with germ cell tumors that had relapsed or were not responding to standard treatment. The approach uses two cycles of paclitaxel and ifosfamide followed by three cycles of carboplatin and etopo…

This study tested a new experimental treatment called HPVST cells in 32 people with HPV-related cancers that had returned or not responded to standard care. The cells are grown from the patient's own blood and trained to attack HPV-infected cancer cells. The goal was to find a sa…

This study tested a precise radiation implant (brachytherapy) for men with low-risk prostate cancer. Instead of treating the whole prostate, doctors placed radioactive seeds only in the tumor area. The goal was to see if this targeted approach could deliver the right radiation do…

This phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…

This study compared two types of radiation therapy for men with intermediate-risk prostate cancer: standard image-guided external beam radiation (IGRT) versus IGRT plus a high-dose-rate brachytherapy boost. The goal was to see which treatment works better and what side effects oc…

This study tested a drug combination (abiraterone acetate plus prednisolone and hormone therapy) given before radiation in 45 men with high-risk localized prostate cancer. The goal was to see if the treatment could shrink tumors and lower PSA levels. The approach aims to improve …

This study tested whether giving two drugs together—Radium-223 and enzalutamide—is safe for men with advanced prostate cancer that has spread to other parts of the body and is no longer controlled by standard hormone therapy. 45 men took part. The main goal was to track serious s…

This study tested a new way to treat intermediate-risk prostate cancer using a 3D map to guide microwaves directly to the main tumor. 76 men across Europe received the treatment, and researchers checked if the cancer was gone after 12 months. The goal is to destroy the cancer whi…

This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…

This phase 2 trial tested a chemotherapy drug called cabazitaxel in 34 men with advanced testicular cancer that had already been treated with at least two other chemotherapies. The goal was to see if cabazitaxel could shrink tumors, including those that spread to the brain. Cabaz…

This phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…

This early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …

This study tested a silicone block placed under the skin of the penis to improve its size, shape, and appearance. It included 40 men who were unhappy with their penile girth or length. The main goal was to check safety and measure changes in size and patient satisfaction.

This study compared two radiation therapy schedules for men with intermediate- or high-risk prostate cancer. One group received fewer, higher-dose radiation sessions (hypofractionated), while the other received standard daily doses. Both groups also received hormone therapy. The …

This study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…

This study looked at whether taking an oral hormone therapy called apalutamide for 6 months could slow down low-risk prostate cancer and delay the need for more aggressive treatments like surgery or radiation. 93 men on active surveillance (watching the cancer without immediate t…

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…

This study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting wors…

This study tested a new way to give radiation to men with intermediate-risk prostate cancer. After standard radiation to the prostate and nearby glands, a precise, high-dose boost was added to the tumor. The goal was to improve cancer control while keeping side effects on the bla…

This early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…

This early-phase trial tested whether rituximab, a drug that depletes B cells, could reduce immune cell infiltration in prostate tumors. Eight high-risk prostate cancer patients received four weekly doses before their scheduled prostate removal. The main goal was to see if B-cell…

This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …

This study looked at 588 men with intermediate-risk prostate cancer to see if adding external beam radiation to brachytherapy (placing radioactive seeds in the prostate) works better than brachytherapy alone. The goal was to see which approach better controls the cancer over time…

This completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…

This study tested a drug called niraparib in 11 men with advanced prostate cancer that was no longer responding to hormone therapy but had recently been treated with platinum chemotherapy. The goal was to see if niraparib could keep the cancer from growing for at least 6 months. …

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…

This early-phase trial tested an experimental cell therapy called INKmune in 12 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find the safest and most effective dose by measuring immune cell activity, PSA levels, and tumor changes. …

This phase 2 trial tested a drug called Lutetium-177-PSMA-617, which delivers radiation directly to prostate cancer cells. It included 58 men with prostate cancer that had spread to a few spots in bones or lymph nodes but was still hormone-sensitive. The study compared the drug t…

This study tested whether adding darolutamide to standard hormone therapy helps men with prostate cancer that has spread to other parts of the body. 669 men participated. The goal was to see if the combination delays cancer growth or death. Results showed improvement in progressi…

This study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …

This study tested a shorter course of proton radiation (5 treatments over 2 weeks) for men with localized prostate cancer, compared to the usual 8 weeks. The goal was to see if this approach maintains quality of life and controls the cancer. 150 men with low- to intermediate-risk…

This study tested a treatment called focused ultrasound (HIFU) that aims to destroy only the cancerous part of the prostate, avoiding common side effects like incontinence and impotence from standard treatments. It involved 174 men aged 50-80 with intermediate-risk prostate cance…

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…

This study tested a radioactive drug called radium-223 in 921 men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal was to see if it helps them live longer and controls the cancer. Participants received either the drug …

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…

This study tested a new surgical clip called VasoClip, designed to hold blood vessels closed more securely during robotic surgery for prostate, kidney, or bladder cancer. Forty patients were randomly assigned to receive either the new clip or a standard clip. The goal was to see …

This Phase 2 study tested a radiation therapy plan that gives a slightly higher dose each day over fewer sessions (16 days instead of the usual 8-9 weeks) for men with early-stage prostate cancer. The goal was to see if this shorter schedule is safe and effective, while also trac…

This study tested a combination of high-dose radiation and hormone therapy (leuprorelin) in 74 men with prostate cancer that had returned in up to 5 pelvic lymph nodes after initial treatment. The goal was to see if this approach could delay further cancer growth or relapse. Part…

This study tested the immunotherapy drug nivolumab (Opdivo) combined with one of three other drugs (rucaparib, docetaxel, or enzalutamide) in 292 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to see if these combinations…

This early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…

This early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…

This study tested a drug called enzalutamide in 1401 men with a type of prostate cancer that has not spread to other parts of the body but is no longer controlled by standard hormone therapy. The goal was to see if enzalutamide could delay the cancer from spreading. Participants …

This study tested whether adding a precise, high-dose radiation treatment (SBRT) to the hormone therapy apalutamide helps control prostate cancer that has stopped responding to standard hormone therapy and spread to a few spots. Twenty-six men with this type of cancer took part. …

This early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…

This early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…

This study tested a new way to treat early-stage prostate cancer using MRI-guided ultrasound waves to destroy tumors without surgery. 25 men with low-to-intermediate risk prostate cancer received the treatment. The main goal was to see if no significant cancer remained one year l…

This phase 2 trial tested two immunotherapy drugs, ipilimumab and nivolumab, in 69 men with a specific type of advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow disease progression. Participants…

This early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…

This study tested whether adding the drug TAK-700 to standard hormone therapy helps men with newly diagnosed prostate cancer that has spread live longer than adding the drug bicalutamide. Over 1,300 men took part. The goal was to see which combination works better for controlling…

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …

This phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and ipilimumab, could shrink tumors or slow progression in men with metastatic castration-resistant prostate cancer. 351 participants received either the combination, ipilimumab alone, or the chemother…

This study tested a drug called niraparib in 289 men with advanced prostate cancer that no longer responds to hormone therapy and has specific DNA repair issues. The goal was to see if the drug could shrink tumors or slow the disease. Results may help identify which patients coul…

This study looked at the long-term safety of the drug degarelix in 57 men with prostate cancer. Participants received a monthly injection of degarelix for up to 5 years. The goal was to monitor side effects, such as changes in blood pressure, pulse, weight, and liver function.

This study tested whether adding a radioactive drug (Radium-223) to targeted radiation (SABR) helps men with prostate cancer that has spread to a few bones or soft tissues. 64 men participated, receiving either SABR alone or SABR plus Radium-223. The goal was to see if the combin…

This large phase 3 trial tested whether adding the chemotherapy drug docetaxel to standard hormone therapy helps men with metastatic prostate cancer live longer. 790 men participated. The results showed that the combination improved overall survival compared to hormone therapy al…

This early-phase study tested a new approach for men with prostate cancer that has spread to nearby lymph nodes. The standard treatment combines radiation with 2-3 years of hormone therapy, which can cause lasting side effects. Researchers added a targeted radioactive drug (Lu-PS…

This early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…

This small pilot study tested a procedure called prostatic arterial embolization in 10 men with low-risk, one-sided prostate cancer who were already on active surveillance. The idea was to block the artery feeding the tumor, starving it of blood. Researchers checked for side effe…

This early-phase trial tested whether injecting a man's own bone marrow stem cells into the penis could help restore erections after prostate cancer surgery. The study included 18 men who had normal erections before surgery but developed erectile dysfunction due to blood vessel d…

This Phase 3 study tested whether adding darolutamide to standard hormone therapy and chemotherapy helps men with metastatic hormone-sensitive prostate cancer live longer. Over 1,300 participants received either darolutamide or a placebo, along with standard treatments. The main …

This early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…

This early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…

This study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…

This study tested a smartphone app to help young adult cancer survivors (ages 18-39) lose weight. The app tracked diet and activity as part of a behavioral weight loss program. The goal was to see if this approach was practical and well-liked by participants. The study involved 6…

This large phase 3 trial tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps men with metastatic hormone-sensitive prostate cancer. Over 1,100 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how lo…

This study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…

This phase 2 trial tested whether adding a radioactive drug (I-131-1095) to standard enzalutamide therapy helps men with a specific type of advanced prostate cancer that had worsened on another treatment. The study enrolled 120 men with PSMA-positive metastatic castration-resista…

This study looked at a small implantable spacer placed between the prostate and rectum in men receiving radiation for prostate cancer. The goal was to see if the spacer reduces the radiation dose reaching the rectum, potentially lowering side effects. A total of 175 men who alrea…

This completed study tested a hydrogel spacer placed between the prostate and rectum in 20 men undergoing radiation for prostate cancer. The goal was to see if the spacer reduces radiation reaching the rectum. Researchers compared rectal radiation exposure before and after insert…

This study tested a combination of two drugs, apalutamide and abiraterone, plus prednisone, in 93 men with advanced prostate cancer that had spread and was no longer responding to hormone therapy. The goal was to see how long the cancer stayed under control and whether the drugs …

This early study tested whether adding a radioactive drug (177Lu-PSMA) to standard brachytherapy is safe and feasible for men whose prostate cancer returned after initial radiation. Only 3 men took part. The goal was to see if the combination could control cancer both in the pros…

This early-phase trial tested a new drug, Karonudib, in 63 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body and any …

This trial tested a steroid injection called triamcinolone in 55 men with castration resistant prostate cancer, a type that no longer responds to standard hormone therapy. The goal was to see if it could extend the time before chemotherapy is needed, since current steroid treatme…

This study looked at men with advanced prostate cancer that no longer responds to hormone therapy. When the standard dose of abiraterone stopped working, some patients received a double dose to see if it could stabilize the disease. The goal was to find out if this approach is sa…

This study tested a new way to treat low-risk prostate cancer using a microwave probe inserted through the rectum. The goal was to see if it could safely destroy the main tumor while protecting nearby tissues. Eleven patients were treated, and the researchers checked for complete…

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…

Researchers are testing whether a combination of PET scans with a radioactive tracer called [18F]PSMA-1007, sodium MRI, and multiparametric MRI can accurately predict where prostate cancer is and how aggressive it is. The study enrolls men who are scheduled to have their prostate…

This study explores whether using only MRI-targeted prostate biopsies—instead of combining them with standard systematic biopsies—can provide enough information for doctors to decide on treatment. Men aged 50 to 75 with suspected prostate cancer and a single suspicious lesion on …

This trial tests whether a new PET/CT tracer, 64Cu-SAR-bisPSMA, can find more sites of prostate cancer recurrence than the standard 68Ga PSMA-11 scan in men whose PSA rises after prostate removal. Fifty men will receive both scans, and researchers will compare how many lesions ea…

This trial explores whether specially trained dogs can identify high-risk prostate cancer by smelling urine samples. Men with suspected prostate cancer will provide urine samples, which six dogs will sniff. The study will compare the dogs' accuracy against MRI results and biopsy …

This trial tests whether a new hybrid tracer, ICG-99mTc-nanoscan, can replace the standard tracer for sentinel node biopsy in people with penile cancer, melanoma, or oral cancer. The hybrid tracer combines a fluorescent dye with a radioactive marker, potentially allowing surgeons…

This large registry study is testing whether a special type of PET scan, called PSMA-PET, can better detect where prostate cancer has returned after initial treatment. Thousands of men with suspected recurrent prostate cancer across Ontario will receive this scan. The goal is to …

This study looks at whether a blood test that detects tumor DNA can find early signs of cancer returning in people treated for HPV-positive pelvic cancers (like cervical or anal cancer). Researchers will take blood samples from 172 patients during regular follow-up visits. The go…

This completed phase 1 trial tested a radioactive imaging agent called [99mTc]Tc-DB8 in 10 people with prostate or breast cancer. The goal was to see how the agent spreads in the body and whether it can help detect tumors using SPECT scans. Researchers also checked for safety and…

This early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…

This completed phase 1 study tested a new radioactive imaging agent called 99mTc-RM26 in 10 people with prostate or breast cancer. The goal was to see how the agent spreads in the body and whether it can help spot tumors using SPECT scans. Researchers also checked for safety and …

This completed Phase 1 study tested a new radioactive tracer called [99mTc]Tc-BQ0413 in 10 men with prostate cancer. The tracer was injected once, and SPECT scans were taken over 24 hours to see where it goes in the body and how safe it is. The goal is to develop a better imaging…

This study tested a new blood test called EPISPOT to find prostate cancer cells in the blood of 361 men with localized prostate cancer before they received any treatment. The goal was to see if this test could predict remission better than an existing test called CellSearch. The …

This study tested a new MRI method that measures temperature changes in the prostate. The goal is to help doctors find cancer more accurately and guide laser treatments. Researchers scanned 70 men who already needed an MRI for prostate cancer diagnosis. The focus was on checking …

This study tested an AI software called Quantib Prostate to see if it can detect prostate cancer on MRI scans as accurately as expert radiologists. Researchers looked at 200 men who had prostate MRIs and biopsies. The AI's readings were compared to the radiologist's readings, usi…

This study looked at tiny particles called extracellular vesicles (EVs) found in prostate fluid from 100 men. The goal was to find unique molecular signatures that could help tell aggressive prostate cancer from slow-growing or benign conditions. Researchers used advanced techniq…

This study tested whether specially trained dogs can identify breast, lung, prostate, or colorectal cancer by sniffing breath samples collected on masks. Over 1,300 people provided breath samples before their regular cancer screening or biopsy. The dogs' results were compared to …

This study tested two different radioactive tracers (68Ga-RM2 and 68Ga-PSMA-617) used in PET/CT scans to see which one better detects prostate cancer in men scheduled for prostate removal surgery. Twenty-two men with low, intermediate, or high-risk prostate cancer received both s…

This study looked at two methods of taking prostate tissue samples to diagnose cancer: one through the rectum and one through the skin between the scrotum and anus. Researchers wanted to see which method causes fewer infections and less bleeding. 101 men with suspected prostate c…

This study looked at 60 men who had a prostate biopsy to check for cancer. It compared two imaging methods used to guide the biopsy: the standard multiparametric MRI and a newer scan called Ga-68 PSMA PET/CT. The goal was to see which method better finds aggressive prostate cance…

This study tested a new type of PET-CT scanner that can scan a tumor right after it is removed from the body. Patients with prostate or head and neck cancer received a small amount of radioactive tracer before surgery, which sticks to cancer cells. After removal, the specimen was…

This study tested a new imaging technique called Full Field Optical Coherence Tomography (FFOCT) to see if it can detect prostate cancer in biopsy samples as well as standard microscope analysis. Researchers compared FFOCT results to the usual pathology exam in 91 men with elevat…

This Phase 3 study tested a radioactive tracer called Copper Cu 64 PSMA I&T, given as an injection, to improve PET/CT scans in 235 men with prostate cancer that may have returned after initial treatment (surgery or radiation). The goal was to see how accurately the scan could det…

This completed registry study at Princess Margaret Cancer Centre tested whether a special PET scan tracer called 18F-DCFPyL (PSMA) can find prostate cancer that has spread to lymph nodes or other organs better than standard CT and bone scans. A total of 142 men with intermediate-…

This study tested a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal was to see if it is safe and to measure how much radiation the body receives. The agent helps doctors see where cancer has spread using a special scan.

This study compared two ways to biopsy the prostate in 275 men with suspected cancer. The standard method takes random samples from the gland, which can miss aggressive tumors or find harmless ones. The new method uses MRI images to guide the needle to suspicious spots. The goal …

This study tested whether new deep learning (AI) technology can make prostate MRI scans faster while still finding suspicious nodules. Researchers compared standard MRI sequences with faster, AI-enhanced versions in 34 adults referred for prostate MRI. The goal was to see if the …

This study tested whether using an MRI to guide prostate biopsies could detect cancer as well as the standard 12-sample systematic biopsy. Researchers enrolled 108 men aged 45-75 with elevated PSA levels and suspicious MRI findings. They compared the cancer detection rates of 3 t…

This study explored whether prostate cancer cells can be detected in blood samples instead of using a needle biopsy. Researchers collected blood from 127 men with suspected prostate cancer and used a special filter to isolate tumor cells. The goal was to see if this non-invasive …

This phase 2 study tested a new radioactive imaging agent called 64Cu-SAR-BBN in 53 men with prostate cancer that had returned after treatment but was not visible on standard PSMA PET scans. The goal was to see if this agent could safely and accurately detect where the cancer had…

This study tested whether a new, high-resolution ultrasound (micro-ultrasound) can find aggressive prostate cancers as well as MRI does during biopsy. Over 800 men with suspected prostate cancer were randomly assigned to one of three biopsy guidance methods. The goal was to see w…

This completed Phase 3 study tested a new radioactive tracer called [18F]CTT1057 for PET/CT scans in 190 men with prostate cancer whose PSA levels were rising after initial treatment. The goal was to see if the tracer could accurately locate where the cancer had returned. Partici…

This study tested a new imaging agent called [18F]CTT1057 for PET scans to see how well it can find prostate cancer tumors. 195 men with high-risk prostate cancer who were scheduled for surgery received the scan. The results were compared to tissue samples taken during surgery to…

This study tested a new imaging agent called 68Ga-NTA-476 for PET scans in 10 men with prostate cancer. The goal was to see how well it finds tumors compared to the standard scan, and to check for side effects. This was the first time this agent was used in humans, so safety and …

This completed study collected urine and blood samples from 80 men, including those with prostate cancer, suspected cancer, or benign prostate enlargement, as well as healthy donors. The goal was to find RNA biomarkers that could lead to a simple liquid biopsy test for diagnosing…

This study tested whether two imaging methods—Histoscanning and multiparametric MRI—can accurately detect and locate prostate cancer that comes back after radiation therapy. Thirty men with rising PSA levels or biopsy-confirmed recurrence were enrolled. Each participant received …

This trial tests whether a software tool called the hypotension prediction index (HPI) can help prevent acute kidney injury after robotic-assisted urologic surgery. The tool uses arterial pressure data to forecast drops in blood pressure during the operation, allowing doctors to …

This trial tests whether a one-hour group discussion helps Latino men aged 50 to 70 make informed decisions about PSA screening for prostate cancer. Participants receive either a printed pamphlet or an interactive session covering the benefits, risks, and controversy around PSA t…

This study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…

This study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…

This study tests whether a personalized 4-week exercise program can improve quality of life and physical function in men with metastatic prostate cancer who are receiving radiation therapy. Eighty participants will either exercise or not, and researchers will track changes in wel…

This study tests a new way to give radiotherapy for men with intermediate-risk prostate cancer. The goal is to lower the dose to healthy parts of the prostate while boosting the dose to the tumor, using a special MRI-guided machine (MR-linac). Twenty men will take part to see if …

This study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…

This completed Phase 2 trial tested whether formal hypnosis, alongside standard care, could reduce anxiety and pain in 68 cancer patients undergoing brachytherapy. Patients received either standard care with Kalinox or standard care plus formal hypnosis. The study measured anxiet…

This trial tests whether an AI emotional companion app can improve depression, anxiety, and demoralization in adults with advanced cancer. Participants use a mobile app where a virtual character holds conversations, reads emotional cues, and offers a link to a human hotline if di…

This trial tests whether regular electronic questionnaires after prostate cancer surgery can improve recovery. Men who have their prostate removed will report symptoms like incontinence and mood through an app or computer. If scores hit certain levels, a nurse calls to offer a ur…

This study tests whether using a virtual reality headset, an aromatherapy patch, or both can help men feel less pain, fear, and embarrassment during a prostate biopsy. About 208 men will be randomly assigned to one of four groups: VR, aromatherapy, both, or standard care. The goa…

This trial tests whether laser acupuncture, a non-invasive therapy using low-intensity light on traditional acupoints, can relieve constipation in people with advanced cancer. Participants are adults with advanced cancer who have constipation despite using laxatives. The study me…

This phase 2 trial tests whether inhaling a blend of peppermint and lemon essential oils can reduce nausea and vomiting in people receiving their first chemotherapy for a solid tumor. Participants will inhale the oils four times daily and whenever nausea strikes, with symptoms tr…

This study tests whether placing ice inside the rectum before a prostate biopsy can lower pain, anxiety, stress hormone levels, and complications like bleeding. About 84 men having their first prostate biopsy will either receive standard care or ice application. The goal is to se…

This trial tests whether a new care approach, called PediQUEST Response, can improve quality of life for children, adolescents, and young adults with advanced cancer. Participants use an app to regularly report symptoms and quality of life, and a palliative care team receives the…

This study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…

This study looks at whether giving a local anesthetic to the abdominal wall at the start of robotic prostate surgery, rather than at the end, can reduce the amount of strong painkillers (opioids) needed during the operation. About 50 adults with prostate cancer or benign prostate…

This study tested whether monthly 45-minute psychological interviews over 6 months could reduce post-traumatic stress symptoms in cancer patients affected by the COVID-19 pandemic. It included 29 adults with solid tumors who had moderate to high PTSD symptoms. The goal was to see…

This study tests whether a 12-week, drug-free exercise program can help men with metastatic prostate cancer who are starting hormone therapy. The program includes supervised sessions of aerobic, resistance, balance, and flexibility exercises. The main goal is to see if patients c…

This trial tests whether adding two surgical steps—suspending the urethra and rebuilding pelvic fascia—during robot-assisted prostate removal can help men regain urinary continence sooner. About 60 prostate cancer patients will receive the modified procedure and be followed for t…

This phase II trial tests whether flibanserin, a drug approved for low sexual desire in women, can increase sexual interest in men with prostate cancer who are receiving androgen deprivation therapy (hormone therapy). About 44 men will be randomly assigned to take flibanserin or …

This study tests a 4-month community program called Men Moving Forward for African-American men who have finished prostate cancer treatment. The program includes twice-weekly sessions to help participants eat more fruits and vegetables, cut down on red meat, and increase physical…

This study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…

This study investigates whether a 12-week program of tai chi and qigong (called Body Mind Training) can reduce fatigue in male cancer survivors aged 55 and older. Participants are randomly assigned to the mind-body training, a light exercise-only group, or a usual-care group. Res…

This study tested whether professional socio-aesthetics (specialized beauty and well-being care) can improve quality of life, reduce pain, and ease anxiety in adults undergoing chemotherapy for lung, breast, colon, or prostate cancer. 400 participants were randomly assigned to re…

This study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…

This pilot study tested a 6-session therapy called Goal-Focused Emotion Regulation Therapy (GET) in 35 young Latino testicular cancer survivors aged 18-39. The therapy helps participants set goals, manage emotions, and find meaning after cancer. Researchers measured anxiety, depr…

This study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…

This small pilot study tested a 3-month program where men with prostate cancer on hormone therapy were encouraged to fast for 12 to 16 hours each night, supported by weekly coaching calls and text messages. The 40 participants found the program feasible and satisfying, with some …

This study tested whether an 8-week program of strength, endurance, and aerobic exercise could reduce fatigue in men with testicular germ cell cancer undergoing chemotherapy. Twenty men participated, with half doing the exercise program and half receiving usual care. The goal was…

This study tested whether using virtual reality hypnosis before chemotherapy infusions could lower anxiety in men with metastatic prostate cancer. Fifty-three patients were randomly assigned to either receive the VR hypnosis session or standard care before each docetaxel infusion…

This study tested a program to help men prepare for and manage side effects from prostate cancer treatments like surgery or radiation. The program used daily texts and emails, plus support from other men, to encourage healthy habits before treatment. The goal was to reduce distre…

This study looked at whether men with metastatic prostate cancer prefer cabazitaxel or docetaxel as their first chemotherapy. 195 patients tried both drugs in sequence and then stated their preference. The goal is to see if side effects like nerve damage or fatigue influence choi…

This study tested whether a prehabilitation program—including exercise, nutrition advice, and education—before robotic prostate surgery helps men regain quality of life more quickly. One hundred men with localized prostate cancer participated. The goal was to see if preparing the…

This study tested whether listening to music during radionuclide treatment helps prostate cancer patients feel less anxious and distressed. Sixty men were split into two groups: one listened to their choice of instrumental music through headphones during treatment, while the othe…

This small pilot study tested whether acupuncture could help reduce hot flashes and night sweats in men with prostate cancer who are on hormone therapy. Twelve men received acupuncture sessions, and researchers measured how well the treatment was accepted and whether symptoms imp…

This study tested a stepped-care telehealth program for cancer survivors living in rural areas who experience anxiety, depression, or sleep problems. Participants received either low-intensity check-ins or high-intensity phone therapy with a licensed therapist, depending on sympt…

This study looked at whether giving a lower dose of the steroid dexamethasone before the chemotherapy drug docetaxel can prevent allergic reactions with fewer side effects. The standard high dose can cause problems like high blood sugar, mood changes, and weakened immunity. Resea…

This study tested whether buffered lidocaine (lidocaine mixed with baking soda) reduces pain during prostate biopsy. 350 men undergoing a prostate biopsy received either buffered or standard lidocaine. Researchers measured pain from the numbing injection and from the biopsy itsel…

This completed trial tested a web-based remote monitoring platform called CONTINUUM+ CONNECT in 411 adults with metastatic breast, lung, colorectal, or prostate cancer. Patients used the platform to report symptoms and receive alerts, aiming to improve their physical health and q…

This study tested whether an online program combining nutrition counseling and resistance training could improve physical function in older adults (65+) who finished treatment for breast, colorectal, or prostate cancer. 75 participants received virtual sessions with dietitians an…

This study tested a remote exercise program for 27 men with prostate cancer who were receiving hormone therapy (androgen deprivation therapy). The program included walking or cycling, strength training, and counseling sessions over 8 weeks. The main goal was to see if the program…

This study looked at whether a 12-week home exercise program using mobile technology could reduce fatigue in cancer survivors. 110 adults who had finished cancer treatment or were on immunotherapy took part. Some also tried acupressure or brief mindfulness exercises. The goal was…

This study tested whether watching 360° virtual reality movies can reduce fear and anxiety in cancer patients about to start radiation therapy. 292 adults with breast, lung, prostate, head and neck cancer, or brain tumors participated. Patients watched a VR movie and then filled …

This study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…

This completed phase 3 trial tested whether taking psyllium husk fiber capsules during pelvic radiation therapy could reduce gut inflammation and urgency symptoms. 354 adults with pelvic cancers (like rectal, prostate, or gynecological) took either fiber or placebo capsules daily…

This study looked at whether showing patients a dynamic video before a prostate biopsy could lower their pain and anxiety compared to just verbal instructions or static images. 223 men aged 50-80 with elevated PSA levels participated. Pain was measured with a Visual Analog Scale …

This study looked at how two prostate cancer drugs, darolutamide and enzalutamide, affect thinking and memory in men with advanced prostate cancer. About 111 men took one of the two drugs and completed computer-based cognitive tests over time. The goal was to see if one drug caus…

This study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…

This study aims to understand why testicular cancer sometimes runs in families. Researchers will collect DNA samples and medical information from about 750 people in families with multiple cases of testicular cancer. No treatment is given; the goal is to find genes that increase …

This study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …

Researchers at a large hospital in Seoul reviewed records from nearly 33,000 adults who had curative-intent surgery for one of seven cancers in the abdomen or pelvis: pancreatic, gastric, rectal, cervical, endometrial, kidney, or prostate. They grouped patients by whether they re…

This study looks at how Spanish-speaking Latiné men cope after prostate cancer treatment, especially with issues like erectile dysfunction and urinary problems. Researchers will survey and interview 55 survivors to understand their needs and cultural barriers. The goal is to crea…

Researchers want to learn which molecules on cancer cells the immune system attacks when checkpoint inhibitor drugs work well. They collect tumor and blood samples from adults with solid tumors who respond to these drugs, either during treatment or after surgery. The team then se…

This study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…

This study looks at how giving fluids during robotic prostatectomy affects patient outcomes. It compares two approaches: one guided by a special monitor (LiDCO) that tracks blood flow in real time, and the other using standard clinical judgment. The researchers will measure the t…

This study looks at whether providing cancer care at home is a good option for Black men with advanced prostate cancer. Researchers want to see if this approach can reduce healthcare disparities and improve quality of life. Participants will fill out questionnaires about their pr…

This study looks at medical records from 584 men in Brazil with castration-resistant metastatic prostate cancer, a form of the disease that no longer responds to hormone therapy. Researchers aim to describe how long these patients survive and to identify their individual characte…

This study explores whether men with early prostate cancer on active surveillance would be willing to take dietary fibre supplements, such as inulin or psyllium. Previous research hints these fibres may reduce inflammation and slow tumour growth, but no one has asked patients abo…

This study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…

This study looks at whether a short risk-assessment tool, called the CARG score, can predict severe side effects from chemotherapy in cancer patients aged 70 and older. Participants will answer questions about their health and daily function before starting a new chemotherapy reg…

This study looked at whether a special website or coaching phone calls could help more people with a personal or family history of certain cancers get genetic testing. Over 800 participants were randomly assigned to one of these two methods or to standard care. The goal was to se…

This trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…

This study looks at genes in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. Researchers will analyze tissue, blood, and urine samples from 92 patients receiving a drug called abiraterone. The goal is to find genetic changes that …

This study follows about 500 men with advanced prostate cancer that still responds to hormone therapy. Researchers are comparing two drug combinations (apalutamide or enzalutamide plus standard hormone therapy) to see how well they work in real-world settings. The goal is to unde…

This study looked at 14 men with intermediate-risk prostate cancer who were scheduled for prostate removal surgery. Each man received two different types of PET scans to see which one better highlights cancer cells. The goal was to compare the scans' ability to detect and measure…

This trial investigates how a single injection of degarelix, a drug that lowers testosterone, affects prostate cancer cells when given just days before prostate removal surgery. Researchers aim to measure changes in cell growth (Ki-67 levels) by comparing biopsy and surgical tiss…

This study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…

This study examines how children under 18 with cancer or a history of a stem cell transplant do when they need a machine called ECMO to help them breathe. Researchers looked at bleeding, infections, and survival rates in children treated at one hospital, and compared survival wit…

This study looks at how robotic surgery for prostate, bladder, or kidney cancer affects patients' finances. Researchers will ask 120 people who had surgery in the last year to fill out questionnaires about their medical costs, travel expenses, and support needs. The goal is to un…

This study looked at whether having a special consultation with a radiotherapy technician (called a manipulator) helps cancer patients feel more informed about their treatment. Researchers enrolled 308 adults with various cancers who were getting radiation therapy. They compared …

This study tested whether Pluvicto, a radioactive drug for prostate cancer, can be safely given through a permanently implanted port (TIVAP) instead of a standard IV. Researchers measured if any drug got stuck in the port in 107 patients. The goal was to see if using the port is …

This study looked at whether it is safe to skip antibiotics before a prostate biopsy. Researchers followed 1753 men who had a biopsy through the perineum (the area between the scrotum and anus). They compared infection rates in those who did not get antibiotics to existing data f…

This completed study looked at 80 patients with advanced prostate cancer that had stopped responding to chemotherapy. All patients received a radioactive drug called 177Lu-PSMA-617. Researchers compared two types of scans—PET and SPECT—to see which better tracks changes in tumor …

This early-phase trial tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 patients with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side eff…

This study looks at how prostate cancer and its treatment affect quality of life three years after diagnosis. Researchers compared 900 men with prostate cancer to cancer-free men of the same age. The goal is to understand what life is like after treatment and whether patients ret…

This study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…

This study looks at whether a special type of PET scan, using two different tracers, can help predict how aggressive a person's prostate cancer is before surgery. Researchers will use computer models to analyze the scan images and compare the results with standard biopsy and surg…

This study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…

This study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…

This study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.

This study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…

This pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.

This study created a massive, secure database of over 14,000 prostate MRI scans from men with or suspected of having prostate cancer. Researchers used this data to train artificial intelligence (AI) models to better tell apart slow-growing from aggressive cancers, predict if canc…

This study looked at how an experimental drug called SHR3680 affects the way the body processes three other common drugs: digoxin, rosuvastatin, and metformin. Thirty-six men with prostate cancer took SHR3680 along with these drugs to see if there were any interactions. The goal …

This early-phase trial tested a fluorescent antibody that attaches to prostate cancer cells. Seven men with moderate- to high-risk prostate cancer received the antibody before robotic prostate removal surgery. The goal was to see if the glowing antibody could help surgeons identi…

This study looked at two ways of giving anesthesia during robotic prostate removal surgery. One method used a low flow of gas (1 liter per minute) and the other used a normal flow (3 liters per minute). The goal was to see which one is better for breathing, heart function, and co…

Researchers at Stanford University tested a new micro-ultrasound device to see if it can more accurately find and outline prostate cancer. The study involved 95 men scheduled for biopsy or prostate removal. The ultrasound images were compared with standard pathology results to he…

This study looked at genetic changes in prostate cancer samples from 84 men who had surgery. The goal was to find DNA markers that could predict if the cancer would come back or spread. By identifying these markers, doctors may one day better tailor follow-up care and treatment f…

This completed study looked at ways to increase diversity in cancer clinical trials, focusing on breast, liver, and prostate cancers. Researchers worked with communities, doctors, and scientists in New York City to find better ways to include people of color and underserved group…

This early-phase trial studied how compounds from black raspberries are absorbed and processed in 60 men with prostate cancer who were scheduled for surgery. Participants ate a black raspberry confection and followed a special diet before surgery. The goal was not to treat cancer…

This study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…

This study looked at 30 men with prostate cancer to understand why MRI and PSMA-PET scans sometimes spot different tumors. Researchers used stored tissue samples to analyze the genes and molecules of these mismatched lesions. The goal was to find out if these differences mean the…

This study aimed to improve how doctors predict whether prostate cancer has spread to nearby lymph nodes. Researchers combined patient information, MRI scans, and genetic data from 367 men who had their prostate removed. The goal was to create a more accurate tool to help decide …

This study looked at 185 men with low-risk prostate cancer who chose active surveillance (monitoring instead of immediate treatment). Researchers used a genetic test called a polygenic risk score to see if it could predict which men would have their cancer get worse over time. Th…

This study tested whether implanting tiny gold markers near spinal tumors helps deliver radiation more accurately. Researchers also checked if giving slightly more radiation to the nearby esophagus is safe, which might improve tumor control. The study involved 41 adults with vari…

This study looked at a new device called AE05ML that helps surgeons place clips on blood vessels and other tissues during keyhole surgery. The goal was to see if the device is safe and works well. A total of 161 adults took part in the study.

This study tested whether a family history app can help doctors collect and use information about patients' family health risks. Over 600 adults aged 30-69 took part. The goal was to see if the app leads to better screening and genetic referrals for conditions like cancer, heart …

This study tested whether an AI tool can help health providers write medical summaries that are easier for patients to understand. 120 providers were split into two groups: one used the AI tool, the other did not. The goal was to see if AI could improve readability and save time,…

This completed study from the University of Aberdeen looked at how dietary fiber supplements might influence prostate cancer. Researchers gave mice different fibers (inulin, pectin, hemp hull) along with stool samples from healthy men over 60. They then measured changes in gut ba…

This study looked at how prostate and colorectal cancer affect mitochondria—the energy factories in cells—and whether a 4-week home exercise program could improve them. Fifteen men awaiting surgery did either resistance or high-intensity interval training at home. Researchers mea…

This study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…

This study tested whether taking dasatinib alone or with darolutamide for 14 days can increase PSMA levels on PET scans in men with metastatic prostate cancer. Only 4 men participated, all with low PSMA uptake on their initial scan. The goal was to learn more about how PSMA expre…

This study tested a tool built into electronic health records that prompts doctors to discuss heart health with cancer survivors during routine visits. Researchers enrolled 645 survivors of breast, prostate, colorectal, endometrial, and lymphoma cancers across 12 clinics. The goa…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study analyzed blood, urine, and tissue samples from 273 adults with brain or lung cancer who were receiving radiation therapy. The goal was to find biological markers that could predict which patients are more likely to develop serious side effects from radiation, such as l…

This completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…

This study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…

This study looked at how often a specific gene change (called HOXB13 c.853delT) occurs in men with prostate cancer in Martinique. Researchers tested 465 men of African descent who had prostate cancer. The goal was to find out how common this gene change is, which may help underst…

This study looked at how closely 200 adults with advanced breast or prostate cancer follow their prescribed oral cancer treatments. Participants filled out questionnaires about their medication use and gave blood samples to check certain health markers. The goal was to understand…

This study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…

This completed study surveyed 51 men with localized prostate cancer and their healthcare providers in Belgium, Italy, and Spain. The goal was to understand how acceptable artificial intelligence (AI) is as a tool to help diagnose prostate cancer, and whether people are willing to…

This study looked at nearly 1,000 cancer survivors to find out which follow-up care model works best for their quality of life and satisfaction. Participants were breast, prostate, or colorectal cancer survivors who had finished active treatment. Researchers compared different ca…

This study tested whether a neighborhood-based educational program could increase knowledge about prostate cancer and screening among 239 men living in high-risk areas. Participants learned about the pros and cons of screening, and researchers measured changes in decision-making …

This study looked at 50 men having robot-assisted prostate surgery to compare two ways of using a breathing machine: flow-controlled and volume-controlled ventilation. The goal was to see which method keeps oxygen levels better and helps the lungs work more smoothly. Researchers …

This study looked at 168 men with metastatic hormone-sensitive prostate cancer to see if a model using PSMA-PET scans and routine medical information could predict how well they would respond to standard first-line treatment. The goal was to help doctors better understand which p…

This study looked at over 1,200 men with advanced prostate cancer who received a radioactive drug called Lutetium-177 vipivotide tetraxetan in real-world clinics. Researchers tracked patient characteristics, treatment patterns, and PSA level reductions. The goal was to see how th…

This study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …

This study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…

This study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…

This study examined medical records of over 6,400 prostate cancer patients who received a treatment called 177Lu-PSMA-617. Researchers wanted to understand the patients' characteristics, treatment patterns, and survival outcomes. The study did not test a new treatment but instead…

This study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…

This study looked at men whose prostate cancer came back after surgery, shown by a small rise in PSA. It compared giving radiation right away versus waiting and doing another special scan when PSA rose higher. Only 4 men took part, so the main goal was to see if such a study is e…

This study translated and tested a Turkish version of the UCLA Prostate Cancer Index, a survey that measures how prostate cancer and its treatment affect daily life. Researchers worked with 115 Turkish-speaking men diagnosed with prostate cancer to check if the new version is rel…

This study looked at oxygen levels inside prostate tumors in 186 men with early-stage prostate cancer. Researchers wanted to see if low oxygen (hypoxia) makes standard treatments like radiation less effective and increases the risk of cancer spreading. Participants had a special …

This study tested a special PET scan tracer called 18F-FAZA to find low oxygen areas (hypoxia) in prostate tumors. Hypoxia can make cancer harder to treat with radiation or chemo. The study involved 18 men with intermediate to high-risk or metastatic prostate cancer. The goal was…

This pilot study tested a web-based tool called MAP (Management of Active surveillance in Prostate Cancer) in 39 men aged 55+ with low-risk prostate cancer who were already on active surveillance. The tool provides education, helps coordinate care with primary care doctors, and o…

This study tested a digital chatbot (called CATALYST) to help cancer survivors learn about genetic testing for inherited cancer risk. Fifty adults who had certain cancers (like breast, ovarian, or prostate) used the chatbot or received usual care. The goal was to see if the chatb…

This study looked at medical records from over 2,700 men with advanced prostate cancer that no longer responds to hormone therapy. Researchers compared two common treatments, enzalutamide and abiraterone, to see which one helped men live longer. The goal was to understand how the…

This study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…

This study followed 25 men who carry BRCA1 or BRCA2 gene mutations (and a control group of non-carriers) to see if they developed prostate cancer. Researchers called participants to update their medical history and check for new diagnoses. The goal is to learn how to better scree…

This study tested a new education program for men with metastatic prostate cancer who are taking next-generation hormone therapy. The program aimed to help patients better understand their disease, stick to their medication, and improve their quality of life. 18 patients took par…

This study analyzed blood samples from 33 men with advanced prostate cancer that no longer responds to hormone therapy. Researchers looked for tiny molecules called microRNAs that might predict whether a patient will resist chemotherapy or newer hormone drugs. The goal is to help…

This study measured how often muscle loss (sarcopenia) happens in men aged 70 and older with prostate cancer who are treated with radiation and hormone therapy. Researchers screened 112 patients using a simple questionnaire and body scans. The goal was to understand risk factors …

This study followed 831 men aged 60 and older with prostate cancer who were starting GnRH agonist therapy (a type of hormone therapy). Researchers measured how their quality of life changed over 6 months, comparing different age groups. The goal was to understand how age affects …

This study tested a program called KanSurvive, which uses virtual education sessions and practice support to help rural primary care clinics improve follow-up care for cancer survivors. Researchers worked with 15 rural practices to see if they could better follow guidelines for m…

This pilot study tested whether a brief educational session with a trained educator could increase the number of men with prostate cancer who agree to germline (inherited) genetic testing. The study enrolled 50 men who met national guidelines for testing but had not yet been test…

This study looked at tiny molecules in the blood called miRNAs to see if they could help doctors tell apart two similar conditions in boys: undescended testicles (which need surgery) and retractile testicles (which usually get better on their own). Researchers took blood samples …

This study tested whether combining PET-CT and MRI scans (called trimodality imaging) can better define the target area for radiotherapy in high-risk prostate cancer. Twenty patients received both standard scans and the new combined scan before treatment. Researchers compared the…

This study looked at whether a special 3D camera can accurately measure radiation from a prostate cancer drug called lutetium. Researchers used data from 20 patients who had already received the treatment. The goal was to see if images taken at different energy levels give the sa…

This study tested a special barbed suture (Symmcora Longterm) used to reconnect the bladder after robotic prostate removal for prostate cancer. Researchers measured how long the stitching took and checked for leaks or other problems up to 6 months after surgery. The goal was to s…

This study compared two common methods for taking a prostate biopsy: one through the rectal wall and one through the skin between the scrotum and anus. 840 men who needed a biopsy for suspected prostate cancer were randomly assigned to one of the two methods. The goal was to see …

This completed study collected MRI and 3D ultrasound images from 2 men with prostate cancer who had their prostate removed. The goal was to create a database that could later be used to train a computer system to detect cancer without needing a biopsy. This is a very early step i…

This study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…

This study asked 167 people with cancer (and their caregivers) what they value most during pharmacy consultations for oral cancer drugs. Using a survey method, researchers identified key preferences to help hospitals design better support services. The goal was to improve patient…

This study looked at the total cost of two types of prostate cancer surgery over 5 years: robot-assisted surgery using the da Vinci system and traditional open surgery. Researchers tracked medical expenses and patient outcomes in 90 men with localized prostate cancer. The goal wa…

This study tested a program for adults aged 65-90 who had breast, colorectal, or prostate cancer. A community health worker assessed their health and provided coaching to address issues often missed after cancer treatment. The goal was to see if the program was feasible and could…

This study looked at how DNA from tumors changes in the blood before, during, and after surgery for breast, prostate, or colon cancer. Thirty adults having curative surgery provided blood samples to measure these DNA levels. The goal was to understand the natural pattern of DNA c…

This study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…

This study followed over 1,400 men with metastatic castration-resistant prostate cancer who were already receiving Radium-223 as part of their routine care. Researchers tracked serious side effects and the development of new cancers over several years. The goal was to better unde…

This study followed 30 men aged 45-70 who had their prostate removed due to cancer. Researchers measured urine leakage by weighing pads over 24 hours and during a 1-hour activity test. The goal was to better understand how long and how severe incontinence lasts after surgery.

This completed study looked at whether special PET scans can predict how aggressive a person's prostate cancer is. Researchers compared scan features with tumor samples from 70 patients who had surgery. The goal was to see if imaging could replace or reduce the need for invasive …

This completed study looked at 261 French cancer patients to understand why many do not exercise, despite evidence that physical activity improves survival and well-being. Researchers surveyed patients about their personality, motivation, anxiety, and social background. The goal …

This small study looked at whether special MRI scans can help doctors adjust radiation treatment for high-risk prostate cancer. Only 5 men took part, all with aggressive cancer. The goal was to see if the MRI method was reliable enough to guide changes in radiation doses. Because…